Phase II study of Favorite (Activaero) shows superiority over conventional Asthma treatment

Results from a Phase II trial in children with mild to moderate Asthma, conducted with the Favorite Inhalation system (budesonide suspension), from Activaero, shows it is effective and holds the promise to become the preferred treatment option when compared to conventional, general purpose therapy. Activaero's Favorite (Flow and Volume Controlled Inhalation Technology) is a drug-device combination consisting of budesonide in liquid formulation and the Company�s proprietary controlled inhalation system and the trial evaluated this against a conventional, general purpose nebulizer, the PARI LC Sprint.

In the two-arm, multicenter pilot trial, conducted with 41 children in Germany, age 3 to 11 years, patients were treated twice daily over 12 weeks and the actual budesonide dose applied with the Favorite was reduced by 75% in comparison to the conventional JET nebulizer since the deposition into the lungs with Activaero's approach is much more efficient. Activaero's treatment enabled pulmonary function benefit (FEV1), along with reduced inflammation (exhaled NO), but it also improved asthma control (C-ACT) and substantially reduced treatment times down to only two minutes, compared to 20 minutes with conventional nebulizer therapy. Activaero now plans to further modify the inhalation system for optimal pediatric use.